An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
|Videos|October 6, 2020
Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma
Author(s)Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.
Advertisement
Sagar Lonial, MD, FACP, professor and chair in the Department of Hematology and Medical Oncology of Emory University School of Medicine and chief medical officer of Winship Cancer Institute of Emory University, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
3
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
4
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
5